Spiracur, a US-based medical device company that designs and develops damaged tissue care solutions, has secured USD20.3m in a series B round of venture capital funding led by Kleiner P
Spiracur, a US-based medical device company that designs and develops damaged tissue care solutions, has secured USD20.3m in a series B round of venture capital funding led by Kleiner Perkins Caufield & Byers and New Leaf Venture Partners.
Existing investor De Novo Ventures also participated in the round.
Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures are US-based venture capital firms.
Previously, Spiracur raised USD4m in venture capital funding.
